

Empaveli (pegcetacoplan)
Effective 08/01/2025

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Contact Information	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Empaveli (pegcetacoplan) is a complement inhibitor indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Coverage Guidelines

Authorization may be reviewed for members new to the plan within the last 90 days who are currently receiving treatment with the requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when all of the following criteria are met:

1. The member has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) confirmed by flow cytometry

Continuation of Therapy

Reauthorization will be granted when all of the following criteria are met:

1. Prescriber submits documentation of a positive response to therapy (e.g., normalization of lactate dehydrogenase [LDH] levels, improvement in hemoglobin levels, decreased number of red blood cell transfusions)

Limitations

1. Initial and reauthorization approvals will be granted for 12 months
2. The following quantity limits apply:

Drug Name and Dosage Form	Quantity Limitation
Empaveli 1080mg/20mL	10 vials per 30 days

References

1. Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry. *Cytometry B Clin Cytom*. 2010; 78: 211-230.
2. Empaveli (pegcetacoplan) injection [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; June 2025.
3. Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. *Hematology*. 2011; 21-29.
4. Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). *Am J Hematol*. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):208-216.

Review History

01/19/2022 – Created and Reviewed for Jan P&T. Effective 03/01/2022.

08/14/2024 – Reviewed and updated at August P&T. Updated criteria to require that the member has a diagnosis of PNH confirmed by flow cytometry. Updated reauthorization criteria to require documentation of a positive response to therapy. Initial and reauthorization requests approved for 12 months. Clarified step therapy language to indicate member must be new to the plan within the past 90 days. Effective 11/01/2024.

07/09/2025 – Reviewed at June P&T. No clinical changes. Effective 08/01/2025.

